Key Factors Influencing Treatment Selection in Relapsed and Refractory Multiple Myeloma

In this segment, the panel discusses the critical factors that guide treatment timing and selection in relapsed and refractory multiple myeloma. Dr. Ajay Nooka invites both Dr. Noopur Raje and Dr. Surbhi Sidana to share their perspectives on how patient- and disease-specific characteristics shape clinical decision-making. The conversation highlights the importance of disease biology, including cytogenetic risk and functional high-risk features, as well as the pace of progression and depth and duration of prior responses. The panel also emphasizes the role of patient-related factors such as performance status, comorbidities, and treatment goals. Together, these considerations help determine the urgency of intervention and the most appropriate therapeutic approach. This segment underscores the need for individualized treatment strategies in multiple myeloma, particularly in patients experiencing early relapse or aggressive disease.